PDCD1 and glioblastoma: Clinical trials for anti-PD-1 treatment in combination with radiotherapy (CheckMate 498, ClinicalTrials.gov Identifier: NCT02617589) and chemoradiotherapy (CheckMate548, ClinicalTrials.gov Identifier: NCT02667587) are currently ongoing where nivolumab is being tested in newly diagnosed GBM patients.